The causative agent of the life-threatening gastrointestinal infectious disease cholera is the Gram-negative, facultative human pathogen *Vibrio cholerae*. We recently started to investigate the potential of outer membrane vesicles (OMVs) derived from *V. cholerae* as an alternative approach for a vaccine candidate against cholera and successfully demonstrated the induction of a long-lasting, high-titer, protective immune response upon immunization with OMVs using the mouse model. In this study, we present immunization data using lipopolysaccharide (LPS)-modified OMVs derived from *V. cholerae*, which allowed us to improve and identify the major protective antigen of the vaccine candidate. Our results indicate that reduction of endotoxicity can be achieved without diminishing the immunogenic potential of the vaccine candidate by genetic modification of lipid A. Although the protective potential of anti-LPS antibodies has been suggested many times, this is the first comprehensive study that uses defined LPS mutants to characterize the LPS-directed immune response of a cholera vaccine candidate in more detail. Our results pinpoint the O antigen to be the essential immunogenic structure and provide a protective mechanism based on inhibition of motility, which prevents a successful colonization. In a detailed analysis using defined antisera, we can demonstrate that only anti-O antigen antibodies, but not antibodies directed against the major flagellar subunit FlaA or the most abundant outer membrane protein, OmpU, are capable of effectively blocking the motility by binding to the sheathed flagellum and provide protection in a passive immunization assay.

The secretory diarrhea human disease cholera is caused by the Gram-negative, motile, curved rod bacterium *Vibrio cholerae* (1). Cholera is transmitted via the fecal-oral route and is characterized by its ability to cause explosive outbreaks. In Asia, the outbreaks peak seasonally before and after the monsoon rain, while in other areas additional factors, such as natural disasters, can contribute to devastating cholera epidemics as was recently observed in Haiti (2–5). Cholera is a major cause of secretory diarrhea in adults, but particularly infants and young children show a high mortality rate in developing countries, where diarrheal diseases remain the second most common cause of death (6, 7). The burden of cholera is difficult to determine because of gross underreporting, but the WHO estimates that 3 to 5 million cases occur per year (8, 9). Treatment of cholera consists essentially of rehydration and antimicrobial agents (5, 10). While the rehydration therapy is highly effective, the availability of the necessary supplies, trained health care staff, and adequate sanitation are often limited during the explosive outbreaks. Hence, besides the therapeutic approach, the further investigation and development of alternative strategies for prevention, such as affordable vaccines, should be a desired goal of the ongoing research.

Currently, the only globally licensed cholera vaccine consists of killed whole-cell *V. cholerae* O1 supplemented with purified recombinant cholera toxin B subunit (11–14). Despite its benefits for travelers in high-risk areas, the vaccine is considered unsatisfactory for broad use in developing countries due to its short shelf life, high cost, and need for cold-chain distribution (15, 16). Closely related reformulations with lower production costs are now marketed. However, only one of them meets the recommended WHO standards, and they still require a cold storage temperature, which could be a big challenge for their broad use in the future (17–20). In addition, live attenuated *V. cholerae* vaccines and conjugate vaccines might provide interesting alternative approaches but are still under development and have not been commercialized so far (21–30). The intensive ongoing research activity in the field highlights the demand for a better cholera vaccine.

We recently started to investigate the potential of outer membrane vesicles (OMVs) derived from *V. cholerae* as an alternative approach for a vaccine candidate against cholera (31–33). OMVs are naturally released by various Gram-negative bacteria and predominantly contain outer membrane components with periplasmic compounds entrapped in the lumen (34, 35). Although we are only beginning to understand the physiological role and biogenesis of OMVs, they are basically nonliving facsimiles of the donor bacterium and can be seen as delivery vehicles for important surface antigens in their native conformation. We demonstrated that immunization of mice by mucosal routes (e.g., intranasal [i.n.] or intragastric) with OMVs derived from *V. cholerae* induced a specific, long-lasting, high-titer immune response (33). The suckling neonates of the primary immunized female mice were protected...
against oral challenge with *V. cholerae*, indicating the induction of a protective immune response upon immunization with OMVs. This indirect protection assay was used, since adult mice are successfully colonized by *V. cholerae* only after pretreatment with antibiotics to decrease the bacterial gut flora. Further characterization revealed that this protective immune response relies upon the transfer of the acquired immunoglobulins (Ig) from the primary immunized female mice to the offspring via breast milk (32).

In addition, the OMV vaccine candidate proved to be highly stable and immunogenic without the requirement of additional adjuvants (31–33). Thus, a cold chain or accessory buffer solutions are unlikely to be required for the OMV vaccine candidate. However, protection against both clinically relevant serogroups O1 and O139 was achieved only by immunization with a mixture of O1 and O139 OMVs. Since O139 has evolved from O1, the two serogroups are closely related but differ in the composition of the lipopolysaccharide (LPS). Hence, the data suggest that antibodies directed against the LPS play a crucial role in protection, although immunization with OMVs also induces a strong immune response against several surface proteins present in the OMVs. Interestingly, we were able to correlate the observed protection in the *in vivo* model with the ability of anti-OMV antibodies to inhibit motility of different *V. cholerae* strains *in vitro*, suggesting that inhibition of motility contributes to protection (31). Noteworthy, *V. cholerae* has a single polar flagellum that is covered by an outer membrane sheath including LPS molecules (36, 37). Thus, we currently propose a model by which antibodies directed against the LPS may block motility by binding to the sheathed flagellum. This inhibition of motility and agglutination of the bacteria is likely to be the critical factor for protection *in vivo*, since flagellar motility is crucial to access the mucosa at the initial stages of colonization (38–42).

Naturally, OMVs contain a relative large amount of LPS, including a hexa-acylated lipid A moiety that potently activates Toll-like receptor 4 (TLR-4) and can result in septic shock (43). Especially parenteral administration routes exhibit a low level of tolerance against the lipid A endotoxin (44–46). The relatively simple administration as well as the robust induction of secretory Ig titers currently argues for immunization with *V. cholerae* OMVs by mucosal routes. However, an ideal vaccine candidate should not be limited to these immunization routes. Moreover, a general reduction of endotoxicity to minimize adverse effects might be necessary for a safe application of the OMV vaccine candidate in humans, as highlighted by a variety of other vaccine candidates containing LPS (47–55). For example, the *Neisseria meningitidis* OMV vaccines, used to control outbreaks in Scandinavia and New Zealand, include an additional step to remove most of the LPS by detergent extraction (56, 57). As will become evident throughout this study, the LPS itself provides the major protective antigen for the *V. cholerae* OMV vaccine candidate. Hence, a simple detergent extraction to substantially decrease the amounts of LPS is not applicable, and an alternative strategy is required.

Here, we present immunization data using LPS-modified OMVs of *V. cholerae*, which allowed us to improve and identify the major protective antigen of the vaccine candidate. Therefore, we constructed defined, in-frame deletion mutants of well-characterized genes involved in the LPS biosynthesis pathway. Subsequently, these genetically engineered *V. cholerae* strains served as OMV donors. Our results indicate that reduction of endotoxicity can be achieved without diminishing the immunogenic potential of the vaccine candidate by genetic modification of lipid A. Subsequently, we attempted to develop a serogroup-independent OMV vaccine by the use of OMVs lacking the O antigen, which is the most important discrimination marker between the serogroups O1 and O139. However, our results indicate that the generation of antibodies against the O antigen portion of the LPS is crucial for the protective immune response.

### MATERIALS AND METHODS

**Bacterial strains and growth conditions.** Bacterial strains and plasmids used in this study are listed in Table 1; oligonucleotides are listed in Table S1 in the supplemental material. *V. cholerae* AC53, a spontaneous streptomycin (Sm)-resistant mutant of the clinical isolate E7946 (O1, El Tor Ogawa), or *V. cholerae* MO10 (Sm-resistant clinical isolate, O139) were used as wild-type (WT) strains representing serogroup O1 [here referred to as WT (O1)] and serogroup O139, respectively. *Escherichia coli* strains DH5αApir and SM10Apir were used for genetic manipulations. If not noted otherwise, strains were cultivated in Luria-Bertani (LB) broth or on LB broth agar plates with aeration at 37°C. To induce TcpA expression, *V. cholerae* was grown in AKI broth (0.5% sodium chloride, 0.3% sodium bicarbonate, 0.4% yeast extract, 1.5% Bacto peptone) for 4 h without shaking, followed by 4 h with aeration at 37°C (58, 59). If required, antibiotics or other supplements were used in the following final concentrations: Sm, 100 μg/ml; ampicillin (Ap), 50 μg/ml in combination with other antibiotics or 100 μg/ml; kanamycin (Km), 50 μg/ml; arabinose (Ara), 0.02%; IPTG (isopropyl-β-D-thiogalactopyranoside), 1 mM; glucose (Gluc), 0.2%; sucrose (Suc), 10%.

**Construction of in-frame deletion mutants and expression plasmids.** The isolation of chromosomal DNA, the PCR assays, the purification of plasmids or PCR products, and the construction of suicide and

<table>
<thead>
<tr>
<th>E. coli</th>
<th>Relevant genotype and description</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>DH5αApir</td>
<td>F- Δ801lacZAM15 ΔargF-lacU169 deoR recA1 endA1 hsdR17 (rK- mK- sK-) supE44 thi-1 gyrA96 relA1, apr-6, Km²</td>
<td>103</td>
</tr>
<tr>
<td>SM10Apir</td>
<td>thi thr leu tonA lacY supE recA::RPa-2::Te: Mu AprR6K, Km²</td>
<td>104</td>
</tr>
<tr>
<td><strong>V. cholerae</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT (O1)</td>
<td>AC33, wild-type <em>V. cholerae</em> strain serogroup O1; biotype, El Tor; serotype, Ogawa; spontaneous Sm² mutant of E7946; clinical isolate from Bahrain, 1978; hapR², Sm²; used for previous immunization studies (31–33, 105)</td>
<td>106</td>
</tr>
<tr>
<td>O139</td>
<td>MO10, wild-type <em>V. cholerae</em> strain serogroup O139; 1992 clinical isolate from India; hapR², Sm²</td>
<td>107</td>
</tr>
</tbody>
</table>

| **ΔwaaL** | ΔwaaL, Sm² | This study |
| **ΔmsbB** | ΔmsbB, Sm² | This study |
| **ΔwaaL, ΔmsbB** | ΔwaaL, ΔmsbB, Sm² | This study |

**Plasmids**

| pCDV442 | oriK, mobRP4, sacB, Ap¹ | 61 |
| p8K | pBAD18-Kan, araBADp, cloning vector, Km² | 108 |
| pΔmsbB | pCDV442::ΔmsbB, Ap¹ | This study |
| pΔwaaL | pKEK229::ΔwaaL, Ap¹ | 76 |
| pwaal | waaL from *V. cholerae* in pBK, Km² | 109 |
| pmsbB | msbB from AC53 in pBBA, Ap¹ | This study |
| pSH2188 | pBAD/Myc-HisA2/flac (six-His) | 66 |
| pET15b-cl-TcpA | clone of AC53 in pMal-p2X (six-His), Ap¹ | 67 |
| pOmpU | ompU of AC53 in pMal-p2X (six-His), Ap¹ | This study |
expression plasmids, as well as the subsequent generation of deletion mutants, were carried out as described previously (60). To construct the suicide plasmid pΔmsbB, upstream and downstream fragments of the gene were PCR amplified using the oligonucleotide pairs msbB_Xbal_1 and msbB_Xhol_2 or msbB_Xhol_3 and msbB_Sphl_4, digested with the appropriate restriction enzyme (New England BioLabs) indicated by the name of the oligonucleotide, and finally ligated into the Sphl/XbaI-digested pCDVD442. Deletion mutants were generated using derivatives of the suicide vector pCDVD442 in combination with the method described by Donnenberg and Kaper (61). Briefly, the respective suicide plasmid was mobilized via conjugation into V. cholerae, and integration of the plasmid on the chromosome was selected by isolating Sm- and Ap-resistant (Sm’ Ap’ ) colonies. Subsequently, sucrose selection was applied to obtain Ap’ colonies and correct deletions were confirmed by PCR (data not shown). To construct the expression plasmid pmsbB, the respective gene was PCR amplified using the oligonucleotides msbBcomp_SacI_1 and msbBcomp_XbaI_2, digested with SacI and XbaI, and ligated into pBAD, which has been digested similarly. The expression plasmid pOmpU was constructed using the oligonucleotide pairs OmpU_Ncol_1 and OmpU_HindIII_2 for amplifying the respective gene and the appropriate restriction enzyme (New England BioLabs) indicated by the name of the oligonucleotide for digestion. Finally, the PCR-amplified fragment was ligated into the NcoI/HindIII-digested pMAL-p2X. Ligation products were analyzed by electrophoresis on a 15% gel and visualized by silver staining (62). A ChemiDoc XRS system (Bio-Rad Laboratories) was used for documentation.

Preparation of OMVs and LPS. OMVs from late-exponential-phase LB broth cultures of V. cholerae were isolated as described previously (33). OMVs from AKI cultures of V. cholerae were isolated accordingly. The protein and LPS concentration of the OMV preparations was estimated with the modified Lowry protein assay (Thermo Scientific Pierce) or by the Purpald assay (see “KDO determination” below). All OMV amounts given below are by protein or LPS amount. LPS of V. cholerae cultures was purified as described previously (31). The concentration of the V. cholerae LPS was determined by comparison to a standard curve of commercially available Escherichia coli O26:B6 LPS (Sigma). LPS was separated on a 15% gel and visualized by silver staining (62). A ChemiDoc XRS system (Bio-Rad Laboratories) was used for documentation.

KDO determination. The Purpald assay, adapted for 96-well microtitre plates, was used to quantify the LPS content in OMV samples (63). Briefly, serial dilutions of 3-deoxy-α-manno-octulosonic acid (KDO) (Sigma) standard and OMV samples were incubated with 50 μl of 32 mM NaO4 for 25 min. Following addition of 50 μl of Purpald reagent (Sigma), the reaction was allowed to proceed for 20 min and stopped by adding 50 μl of 64 mM NaNO3. After addition of 20 μl of 2-propanol, the absorbance at 550 nm was determined.

Protein analysis by MS. The respective protein band was excised from the gel and tryptically digested according to the method of Shevchenko et al. (64). Peptide extracts were dissolved in 0.1% formic acid and separated on a nano-high-performance liquid chromatography (HPLC) system (Ultimate 3000; Dionex, Amsterdam, Netherlands). Samples of 70 μl were injected and concentrated on the loading column (LC Packings C18 PepMap, 5-μm particle size, 100-Å pore size, 300 μm inside diameter [i.d.] by 1 mm) for 5 min using 0.1% formic acid as an isotropic solvent at a flow rate of 20 μl/min. The column was then switched to the nanoflow circuit, and the sample was loaded onto the nanocolumn (LC-Packings C18 PepMap, 75-μm i.d. by 150 mm) at a flow rate of 300 nl/min and separated using the following gradient: solvent A, water, 0.3% formic acid; solvent B, acetonitrile-water, 80:20 (vol/vol), 0.3% formic acid; for 0 to 5 min, 4% B; after 40 min, 55% B; then, for 5 min, 90% B; and finally 47 min of reequilibration at 4% B. The sample was ionized in a Finnigan nano-ESI source equipped with NanoSpray tips (PicoTip Emitter; New Objective, Woburn, MA, USA) and analyzed in a Thermo Finnigan LTQ linear ion trap mass spectrometer (Thermo, San Jose, CA, USA). The tandem mass spectrometry (MS/MS) data were analyzed with SpectrumMill Rev. 03.03.084 SR4 (Agilent, Darmstadt, Germany) software using a V. cholerae proteome database (ftp://ftp.jcvi.org/pub/data/Microbial_Genomes/v_cholerae_el_tor_n16961/annotation_dbs/v_cholerae_el_tor_n16961.1.pep).

Hydroxylated fatty acid analysis of the LPS. To determine differences in the hydroxy-fatty acid content of the WT (O1) and ΔmsbB mutant LPS, cultures (125 ml) of the respective strains were grown to the late exponential phase. Cells were harvested by centrifugation, and the pellet was washed twice with 40 ml phosphate-buffered saline (PBS). Phospholipids were removed from the samples by two washing steps according to the method of Folch et al. (65), followed by four washing steps with chloroform-methanol (2:1, vol/vol). Removal of phospholipids was confirmed by analysis of the supernatants after the second and sixth washing steps using an RP-UPLC-QTOF-MS system (Waters, Manchester, United Kingdom) (see Fig. S1 in the supplemental material). The remaining pellet was resuspended in methanol and transferrred to a Pyrex glass tube, and the supernatant was removed after centrifugation. The fatty acids were transesterified using 2 ml boron trifluoride in methanol and 0.5 ml toluene. After 2 h of incubation at 100°C, 1 ml ice-cold water was added, and methyl esters were extracted twice with 2 ml hexane. The samples were dried under a stream of nitrogen, and the hydroxyl groups were silylated by incubating with 60 μl BSTFA [N,O-bis(trimethylsilyl)trifluoroacetamide]-pyridine (1:2, vol/vol) at room temperature for 30 min. Gas chromatography (GC)-MS was performed using the Trace GC and DSQ-MS (Thermo Scientific, Vienna, Austria). One microlitre of sample solution was injected (injector temperature, 250°C) and separated on a 60-m DB5-MS column (gradient from 80 to 300°C) (Agilent, Waldbronn, Germany). MS data were acquired in positive electron impact (EI) ionization mode (70 eV; source temperature, 280°C; mass range, 50 to 700 m/z). Data analysis was performed using the XCalibur 1.4 software (Thermo). The peaks (see Fig. S2 in the supplemental material) in the extracted ion chromatograms of m/z 287 (= M-15) for trimethylsilyl (TMS)-3-hydroxylauroylmethylether and m/z 315 (= M-15) for TMS-3-hydroxymyristoyl methyl ester were integrated, and the ratios of the peak areas were calculated (see Fig. S3 in the supplemental material).

Purification of proteins and immunization. The His-tagged proteins FlaA and TcpA were purified using the expression plasmids pSSH2188 and pET15b-cI-TcpA as described previously (66, 67). For the expression of OmpU, cultures of E. coli DH5α containing pOmpU were grown in 500 ml LB containing 100 μg/ml ampicillin for 4 h and induced with 1 mM IPTG for another 4 h. Cells were pelleted and resuspended in binding buffer (20 mM sodium phosphate, 0.5 M NaCl, 10 mM imidazole [pH 7.4]) with 8 M urea. His-tagged OmpU was purified using a HitTrap HR column (GE Healthcare) according to the manufacturer’s instructions. In order to generate high-titer IgG1 antisera against FlaA and OmpU, the respective purified His-tagged proteins (100 μg protein per immunization) were used to intraperitoneally (i.p.) immunize mice on days 0, 14, and 28. Finally, sera were collected on day 40.

Polynymixin B assay. Overnight cultures of V. cholerae were subcultured 1:10,000 into LB. Samples of 100 μl bacterial culture were placed into wells of a 96-well plate and 11.1 μl of the 1:2 serially diluted peptide solution (at a concentration 10 times higher than the final concentration) was added. After 18 h of incubation in a humid chamber at 37°C, the optical density at 600 nm (OD600) was measured using the FLUOstar Omega Microplate Reader (BMG Labtech).

TNF-α, IL-1, and IL-6 induction assays. For tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), and IL-6 induction assays, a confluent layer of RAW macrophages was stimulated with OMVs (100 ng/ml) derived either from WT (O1) or from ΔmsbB for 6 h before the RNA was isolated. Nonstimulated RAW macrophages grown in parallel served as a control. To isolate the RNA, RAW macrophages were washed once with PBS and suspended in 600 μl TRIzol/well (Invitrogen). Following chloroform extraction, RNA was precipitated with isopropanol. An aliquot of the RNA (1 μg) was used as the template to synthesize cDNA using the iSCRIPT Select cDNA Synthesis kit (Bio-Rad Laboratories) according to the manufacturer’s instructions. Quantitative reverse transcription-PCR (qRT-PCR) experiments were performed in triplicates with SYBR
GreenER qPCR SuperMix for the ABI Prism instrument (Invitrogen), utilizing a Rotor-Gene 600 and Rotor-Gene 600 Series Software 1.7 (GenXpress) according to the manufacturer’s instructions. The sequences of the oligonucleotides used in this study are listed in Table S1 in the supplemental material. All measured mRNA levels were normalized to the expression of the housekeeping gene RPLP0 (36B4). Values above or below 1 indicate induction or repression, respectively, of the respective gene in OMV-stimulated RAW macrophages compared to nonstimulated RAW macrophages.

**Animals.** Female BALB/c mice (Charles River Laboratories) were used in all experiments in accordance with the rules of the ethics committee at the University of Graz and the corresponding animal protocol, which has been approved by the Austrian Federal Ministry of Science and Research Ref. II/10b. Mice were housed with food and water ad libitum and monitored under the care of full-time staff. All animals were acclimated for 1 week before any procedures were carried out and were approximately 9 weeks old at the start of the immunization.

**OMV immunization protocol and neonatal challenge with V. cholerae.** Nine-week-old female mice were i.n. immunized at days 0, 14, and 28 with 25 μg of OMVs in PBS as described previously (32, 33). Mice were briefly anesthetized by inhalation of 2.5% isoflurane gas prior to all immunizations. A group of sham (PBS)-immunized control mice were housed in parallel with immunized mice for the duration of each experiment. Two independent immunization rounds were performed with at least three mice per group. Both immunization rounds revealed no differences in the induced protective immune response in the respective immunization groups. Mice were mated on day 41, and 5- to 6-day-old neonates were challenged with V. cholerae as previously described (32, 33). Neonatal mice from a given litter were split into two groups and infected with either V. cholerae O1 or O139 to obtain challenge data for both serogroups. Briefly, for the challenge, the 5- to 6-day-old neonates of immunized and sham-immunized mice were separated from their dams for 1 h, anesthetized by inhalation of 2.5% isoflurane gas, and orally infected with approximately 6 × 10^8 CFU/mouse (exact input doses ranged from 3.4 × 10^8 to 2.3 × 10^7 CFU/mouse), which is about 40-fold (O139) or 300-fold (O1) the 50% infective dose (ID₅₀) (31–33). Infected mice were then sacrificed, and the small intestine was removed from each neonatal mouse by dissection and mechanically homogenized in 1 ml LB with 20% glycerol. Appropriate dilutions were plated on LB plates supplemented with Sm to determine viable counts. The limit of detection was 10 CFU/small intestine.

In addition, a passive protection study using purified antisera in combination with the infant mouse model was performed to assess the protective quality of antisera directed against certain surface antigens in more detail. The anti-IgG1 titer of each serum was determined via enzyme-linked immunosorbent assay (ELISA) using the appropriate coating antigen (OMVs, FlaA, OmpU, or LPS) to allow an adjustment to equal concentrations in the assay. For the in vivo study, V. cholerae O1 culture was adjusted to an OD₆₀₀ of 0.16, and mixed with heat-inactivated serum (56°C, 30 min) in a 1:2 ratio to achieve a final titer of 6 μg/ml anti-IgG1 in the same experiment. V. cholerae was taken from an LB plate supplemented with Sm, resuspended in LB broth at an OD₆₀₀ of 0.16, and mixed with heat-inactivated serum (56°C, 30 min in a 1:2 ratio to achieve a final IgG1 titer of 6 μg/ml). After 10 to 30 min of incubation at room temperature, 5 μl of the culture was placed on a slide under a coverslip and viewed with a 40× objective by dark-field microscopy (Olympus CH-2). Motile bacteria appeared as lines or swirls, whereas nonmotile bacteria appeared as bright dots. The images were taken using a 456-ms exposure (TCA-3.0C; Mueller, Germany). To analyze the viability of the bacteria after sample treatment, V. cholerae was mixed with the respective sera as described for the motility assay (see above). After 10 to 30 min of incubation at room temperature, samples were rigorously vortexed to dissolve potential aggregates, and appropriate dilutions were plated for CFU counts.

**Statistical analysis.** Data were analyzed using the Mann-Whitney U test or a Kruskal-Wallis test followed by post hoc Dunn’s multiple comparisons. Differences were considered significant at P values of <0.05. For all statistical analyses, GraphPad Prism version 4.0a was used.

**RESULTS**

OMVs derived from ΔmsbB and ΔwaaL mutants are defined by alterations in the LPS. MsbB (also referred to as LpxN) was recently characterized as a functional secondary lipid A acyltransferase of V. cholerae, which is required for transferring a 3-hydroxylaurate to the 3′ position of the glucosamine disaccharide (70). Consequently, an msbB mutant strain lacks a 3-hydroxylaurate of lipid A, resulting in LPS that is underacylated compared to that of WT (O1). In general, such underacylated LPS has been demonstrated to exhibit less endotoxicity due to reduced stimu-
loration of TLR-4 (70–74). We constructed a \(\Delta msbB\) strain to test if the OMVs with underacylated LPS exhibit less endotoxicity but retain their immunogenicity.

The hydroxyl group of the 3-hydroxylaureate transferred by MsB serves as the site of a glycin modification, which in turn confers resistance to polymyxin B (75). Consequently, \(msbB\) mutants have been demonstrated to exhibit an increased polymyxin B sensitivity (70, 71). In concordance with these reports (70, 71, 75), the \(\Delta msbB\) mutant with the empty vector control displayed a higher sensitivity to the antimicrobial peptide polymyxin B than did WT (O1) with the empty vector control (see Fig. S4 in the supplemental material). This defect was partially complemented by the expression of \(msbB\) in trans. An incomplete rescue of this nature is not surprising, given the fact that expression levels from inducible plasmids rarely match the same levels detected in the wild type and slightly altered amounts of membrane associated enzymes might already affect membrane integrity. Accordingly, partial complementation has been reported previously for other LPS biosynthesis gene products (76–78).

Furthermore, we visualized the LPS of WT (O1) and \(\Delta msbB\), both containing the control plasmid, as well as the complementation strain by SDS-PAGE and silver staining (Fig. 1). The WT (O1), \(\Delta msbB\), and \(\Delta msbB\) pmsB strains exhibited similar migration patterns of the LPS bands as well as comparable levels of the fully synthesized LPS (Fig. 1, lanes 1, 5, and 6). Finally, we determined the ratio of 3-hydroxylaureate to 3-hydroxyxymristate in phospholipid-purified LPS samples derived from WT (O1) and the \(\Delta msbB\) mutant by mass spectrometry to reveal the fatty acid missing in the \(\Delta msbB\) mutant. A proportional reduction of 3-hydroxylaureate for the \(\Delta msbB\) mutant LPS compared to the WT (O1) LPS was observed (see Fig. S3 in the supplemental material). This result is consistent with a comprehensive lipid A analysis of a \(\Delta msbB\) mutant reported previously by Hankins et al. (70), which already demonstrated that MsB transfers a 3-hydroxylaureate to the 3′-linked primary acyl chain of \(V.\ cholerae\) lipid A. In summary, the LPS of the \(\Delta msbB\) mutant lacks one fatty acid in lipid A, while further synthesis of the LPS and the attachment of the O antigen are not affected.

To investigate the endotoxicity, RAW macrophages were stimulated \textit{in vitro} with purified OMVs derived either from WT (O1) or the \(\Delta msbB\) mutant. Subsequently, RNA was isolated from the OMV-stimulated macrophages and assayed for the induction of inflammatory markers like TNF-\(\alpha\), IL-1\(\beta\), and IL-6 via qRT-PCR (Fig. 2). Nonstimulated RAW macrophages grown in parallel served as a control. As expected, the expression of all three cytokines, which are part of the inflammatory response pathway activated by LPS, was greatly induced by WT (O1) OMVs, ranging from 30-fold for TNF-\(\alpha\) to 20-fold for IL-1\(\beta\) and 9,000-fold for IL-6. In contrast, the inflammatory response after stimulation with \(\Delta msbB\) OMVs was much weaker and reached only 10 to 50% of the level detected for WT (O1) OMVs. This indicates a significant lower endotoxicity of the \(\Delta msbB\) OMVs due to its underacylated, detoxified LPS.

In addition to the \(\Delta msbB\) mutation, we created a second OMV donor strain and additionally deleted waaL, encoding the functional O antigen ligase of \(V.\ cholerae\) (79). Hence, the LPS of the \(\Delta waal\) \(\Delta msbB\) mutant consists of an underacylated lipid A and lacks the O antigen. The latter was confirmed by visualization of the LPS by SDS-PAGE and silver staining (Fig. 1, lane 2). The \(\Delta waal\) \(\Delta msbB\) mutant shows only the lipid A core oligosaccharide (lipid A-core OS) without any O antigen attached. The expression of \(waal\) in trans, but not that of \(msbB\), restored the attachment of the O antigen and the presence of fully synthesized LPS (Fig. 1, lanes 3 and 4).

Furthermore, we analyzed the protein profile of the purified OMVs derived from WT (O1), \(\Delta msbB\), and \(\Delta waal\) \(\Delta msbB\) by SDS-PAGE in combination with Kang’s staining method (Fig. 3). In comparison to the protein profile of the WT (O1) OMVs, the \(\Delta msbB\) OMVs lack one band of approximately 28 kDa and the \(\Delta waal\). \(\Delta msbB\) OMVs exhibit an increase of some high-molecular-weight bands and two protein bands at approximately 40 kDa (Fig. 3, lanes 1, 2, and 3). Such changes might indicate a role of the LPS in the sorting of the OMV cargo, which is currently being investigated in our laboratory. In summary, although the mutant strains display distinct differences in their OMV protein profiles, the most abundant protein bands between 25 and 46 kDa are present in all OMVs analyzed (Fig. 3).

Immunization with OMVs derived from \(\Delta msbB\) and \(\Delta waal\). \(\Delta msbB\) induces a robust immune response. To characterize the
immunogenic properties of OMVs derived from the WT (O1), ΔmsbB, and ΔwaaL ΔmsbB strains, we i.n. immunized female mice with 25 μg (protein equivalents) per immunization of the respective OMVs according to our standard immunization protocol, which consists of an initial immunization followed by two boosts at days 14 and 28 (33). As will become evident below, the LPS present in the OMVs plays a crucial role for induction of a protective immunity. Thus, we also quantified the LPS content of the OMVs using a Purpald assay (63), which revealed comparable amounts of LPS in OMV samples derived from WT (O1), ΔmsbB, and ΔwaaL ΔmsbB (see Table S2 in the supplemental material). Hence, the OMV samples derived from WT (O1) and mutant strains used for the immunization studies contained similar amounts of protein as well as LPS. Mice sham immunized with PBS served as a nonvaccinated control group. The temporal immune responses and the half-maximum total Ig titers in sera of immunized or nonvaccinated female mice were monitored by ELISA using WT (O1) OMVs as coating material. As an example, the progression of the temporal IgG1 response is shown in Fig. 4 for all immunization groups. At day 0, the median IgG1 titers to WT (O1) OMVs were relatively low and showed no significant differences between the groups tested. In general, the IgG1 titers of all immunization groups increased during the vaccination period, with the highest level detected on day 86. Noteworthy, the mice immunized with WT (O1) or ΔmsbB OMVs showed similar median IgG1 titers at the endpoint of the experiment, while the median IgG1 titer of the mice immunized with ΔwaaL ΔmsbB OMVs was significantly lower (P < 0.05; Mann-Whitney U test). The antibody titers of the nonvaccinated control group were monitored at the beginning and the end of the experiment and remained below the limit of detection for both time points (data not shown).

Additionally, we determined the half-maximum total Ig titers against WT (O1) and ΔwaaL ΔmsbB OMVs in sera collected from immunized mice as well as from nonvaccinated mice at day 86 (Fig. 5A and B). The quantification of the total immune response allowed us to compare the overall immunogenicity and the effectiveness of each tested vaccine candidate. The median half-maximum total Ig titers of all immunization groups were significantly higher than those of the nonvaccinated control group (P < 0.05; Kruskal-Wallis test and post hoc Dunn’s multiple comparisons). Consistent with the temporal immune response, the mice immunized with ΔwaaL ΔmsbB OMVs showed a significant 4-fold-lower level of the half-maximum total Ig-titers compared to the WT (O1) OMV immunization group (P < 0.05; Kruskal-Wallis test and post hoc Dunn’s multiple comparisons). It should be noted that these Ig titers were determined by ELISA using WT (O1) OMVs as coating material. Based on the observed alterations in the protein profile and LPS in the double mutant, it could be speculated that mice immunized with ΔwaaL ΔmsbB OMVs developed a slightly different specificity of the immune response compared to the mice immunized with WT (O1) OMVs. For example, ΔwaaL ΔmsbB OMV-immunized mice might have raised...
antibodies against antigens, which are either masked or less abundant in WT (O1) OMVs. Thus, analysis of the immune response using WT (O1) OMVs as coating antigen might not be the best approach to detect the overall induced immune response in ΔwaaL ΔmsbB OMV-immunized mice. Therefore, we reanalyzed the half-maximum total Ig titers of all groups using ΔwaaL ΔmsbB OMVs as coating material (Fig. 5B). This alternative analysis resulted in higher median half-maximum total Ig titers for the ΔwaaL ΔmsbB OMV-immunized mice, while the titers of the other groups remained at a similar level, independent of the coating antigen. Consequently, the half-maximum total Ig titers of the WT (O1) OMV and ΔwaaL ΔmsbB OMV-immunized mice were not significantly different when ΔwaaL ΔmsbB OMVs were used as coating material. In summary, all immunization groups displayed a robust immune response with similar levels of Ig titers, but the results obtained by ELISA suggest differences in the specificity of the immune response.

Immunization with OMVs derived from WT (O1) or ΔwaaL ΔmsbB elicits different antibody specificity to LPS. To investigate the specificity of antibodies against proteins present in the OMVs, immunoblot analysis was performed using WT (O1) and ΔwaaL ΔmsbB OMVs as antigens. Representative immunoblots were incubated with sera collected at day 86 from one mouse of each immunization group as well as from the nonvaccinated control group (Fig. 6). No bands were detected on immunoblots using sera from nonvaccinated control group mice (data not shown). In concordance with previous studies (33), multiple bands were detected in the OMV protein profile using sera of immunized mice. Similar band patterns appeared without obvious differences in any sera of the three immunization groups. Thus, the groups immunized with OMVs derived from WT (O1), ΔmsbB, or ΔwaaL ΔmsbB OMVs induced a similar antibody specificity on the protein level. Furthermore, the most immunogenic proteins, relevant for the detected antibody response, have to be present in WT (O1), ΔmsbB, or ΔwaaL ΔmsbB OMVs.

Next, we analyzed the immune response and antibody specificity raised against the LPS structure by ELISA and dot blot analysis. We determined the half-maximum total Ig titers in sera from OMV-immunized mice. (A and B) Half-maximum total Ig titers to LPS isolated from WT (O1) (A) or ΔwaaL ΔmsbB (B). Results are shown for sera collected at day 86 from mice intranasally immunized with WT (O1) OMVs, ΔmsbB OMVs, and ΔwaaL ΔmsbB OMVs and from the nonvaccinated control group (n ≥ 6 for each group). The error bars indicate the interquartile range of each data set. Significant differences between the data sets are indicated by asterisks (P < 0.05; Kruskal-Wallis test and post hoc Dunn’s multiple comparisons). (C, D, and E) Dot blot analysis of total Ig reactivity against LPS in sera from mice immunized with WT (O1) OMVs (C), ΔmsbB OMVs (D), or ΔwaaL ΔmsbB OMVs (E). Representative dot blots were loaded with purified WT (O1) LPS as well as ΔwaaL ΔmsbB LPS as indicated above each blot and incubated with sera collected at day 86 from immunized mice of the respective immunization groups. Different amounts of the isolated LPS ranging from 0.4 to 4 μg were absorbed on a nitrocellulose membrane as indicated on the left side.

![Figure 6](http://iai.asm.org/)

**FIG 6** Immunoblot analysis of the IgG reactivity against *V. cholerae* surface proteins in sera from OMV-immunized mice. Representative immunoblots were loaded with WT (O1) OMVs as well as ΔwaaL ΔmsbB OMVs as indicated above each blot and incubated with sera collected at day 86 from mice immunized with WT (O1) OMVs (A), ΔmsbB OMVs (B), or ΔwaaL ΔmsbB OMVs (C). Lines to the left indicate the molecular masses of the protein standards in kDa.

![Figure 7](http://iai.asm.org/)

**FIG 7** Characterization of the immune response against LPS in sera from OMV-immunized mice. (A and B) Half-maximum total Ig titers to LPS isolated from WT (O1) (A) or ΔwaaL ΔmsbB (B). Results are shown for sera collected at day 86 from mice intranasally immunized with WT (O1) OMVs, ΔmsbB OMVs, and ΔwaaL ΔmsbB OMVs and from the nonvaccinated control group (n ≥ 6 for each group). The error bars indicate the interquartile range of each data set. Significant differences between the data sets are indicated by asterisks (P < 0.05; Kruskal-Wallis test and post hoc Dunn’s multiple comparisons). (C, D, and E) Dot blot analysis of total Ig reactivity against LPS in sera from mice immunized with WT (O1) OMVs (C), ΔmsbB OMVs (D), or ΔwaaL ΔmsbB OMVs (E). Representative dot blots were loaded with purified WT (O1) LPS as well as ΔwaaL ΔmsbB LPS as indicated above each blot and incubated with sera collected at day 86 from immunized mice of the respective immunization groups. Different amounts of the isolated LPS ranging from 0.4 to 4 μg were absorbed on a nitrocellulose membrane as indicated on the left side.
control group (P < 0.05; Kruskal-Wallis test and post hoc Dunn’s multiple comparisons). In contrast, the detected immune response against LPS in sera of the ΔwaaL ΔmsbB OMV immunization group depends on the coating material. Against purified WT (O1) LPS, this immunization group exhibits only low half-maximum total Ig titers, which were not significantly different from those of the nonvaccinated control group (P < 0.05; Kruskal-Wallis test and post hoc Dunn’s multiple comparisons). However, the half-maximum total Ig titers of the ΔwaaL ΔmsbB OMV immunization group were much higher when purified ΔwaaL ΔmsbB LPS was used and reached levels comparable to those of the groups immunized with WT (O1) or ΔmsbB OMVs.

We performed dot blot analysis to confirm the differences in the specificity of the LPS antibody response observed by ELISA. Dot blots were loaded with serial dilutions of the purified full-length WT (O1) LPS or ΔwaaL ΔmsbB LPS and subsequently incubated with sera collected from immunized mice (Fig. 7C to E). Neither the full-length nor the precursor LPS was detected on dot blots using sera from nonvaccinated control group mice (data not shown). The lipid A-core OS precursor was detected at similar intensities by the sera of all immunization groups in a concentration-dependent manner (Fig. 7C to E, right lanes). This indicates that the lipid A-core OS serves as an immunogenic antigen in all OMV-immunized mice. In contrast, the full-length LPS could be detected only using sera of WT (O1) or ΔmsbB OMV-immunized mice, but not using sera of ΔwaaL ΔmsbB OMV-immunized mice (Fig. 7C to E, left lanes). This suggests that only mice immunized with OMVs containing full-length LPS with attached O antigen antibodies that are capable of recognizing such full-length LPS. This indicates that only the mice immunized with WT (O1) or ΔmsbB OMVs have raised antibodies against the O antigen and most of the immune response against the LPS in these immunization groups is indeed directed against the O antigen. In summary, the difference in the antibody specificity directed against the LPS with attached O antigen discriminates between the immune response induced in mice immunized with WT (O1) and ΔmsbB OMVs and that induced in the group immunized with ΔwaaL ΔmsbB OMVs.

OMVs lacking the O antigen fail to induce a protective immune response. In order to investigate whether the induced humoral immune response also results in protection against V. cholerae infection, we used a modified version of the infant mouse model, wherein the offspring of immunized dams were challenged and the level of protection was measured by the degree of colonization in the small intestine. Since protection in our model correlates mainly with the access to breast milk from immunized dams, the infected neonatal mice were given back to their respective dams for the challenge period (32, 33). In order to investigate the protection against both clinically relevant serogroups, the offspring of each immunization group were divided into subgroups and challenged orally with approximately 6 × 10^5 CFU/mouse with either the homologous V. cholerae strain O1 or the heterologous strain O139. These infection doses correspond to 40-fold (O139) or 300-fold (O1) the ID_{50} and have been used previously for challenge experiments (31–33). The results are presented in Fig. 8. In the case of a challenge with serogroup O1, neonatal mice of the nonvaccinated control group as well as of the ΔwaaL ΔmsbB immunization group were stably colonized with a median colonization level of around 10^5 to 10^6 CFU/small intestine (Fig. 8A). In contrast, neonatal mice from WT (O1) or ΔmsbB OMV-immunized mice showed a significantly reduced colonization or were completely protected from colonization with serogroup O1. Challenging neonatal mice from dams immunized with any OMV derivatives with a heterologous V. cholerae strain (O139) resulted in colonization with similar numbers of recovered CFU of approximately 10^4 CFU/small intestine (Fig. 8B). Taken together, the results of the challenge experiments reveal a correlation between the presence of antibodies directed against the respective O antigen and the induction of a protective immune response. Consequently, all immunization groups showed no protection against O139, and the mice immunized with ΔwaaL ΔmsbB OMVs failed to demonstrate protection against O1 and O139.

The presence of antibodies directed against an abundant surface structure, such as the O antigen, is ostensibly crucial for a protective immune response. Interestingly, the toxin-coregulated pilus (TCP) of V. cholerae, which represents an important colonization factor, is also an associated surface structure and was reported to be a protective antigen in a passive immunization study using the infant mouse model (67, 80, 81). We wanted to test whether the lack of the O antigen can be compensated for by the presence of the TCP representing an alternative surface antigen.

**FIG 8** Homologous and heterologous V. cholerae challenge of neonates born to mice immunized with OMVs derived from WT (O1), ΔmsbB, and ΔwaaL ΔmsbB. The numbers of recovered CFU/small intestine are shown for neonates born to immunized as well as nonvaccinated mice, which were challenged with WT serogroup O1 (A) or WT serogroup O139 (B). Each circle represents the number of CFU from one neonatal mouse, and the horizontal bar indicates the median of each data set. Neonatal mice were challenged with an infection dose approximately 300- or 40-fold greater than the ID_{50} for O1 or O139, respectively. When no bacteria were recovered, the number of CFU was set to the limit of detection of 10 CFU/small intestine (dotted line). The numbers of infected mice are given above the respective data set as the ratio of the number of mice with detectable colonization to the total number of challenged mice. Significant differences between the data sets are indicated by asterisks (P < 0.05; Kruskal-Wallis test and post hoc Dunn’s multiple comparisons).
Thus, OMVs derived from ΔwaaL ΔmsbB were purified under TCP-expressing conditions using AKI broth (58, 59). In the protein profile of the ΔwaaL ΔmsbB OMVs grown under AKI conditions, a band at approximately 18 kDa is more intense than the same band for OMVs derived from the isogenic strain grown in LB broth (Fig. 3, lane 4). Analysis by mass spectrometry of this band yielded a mass that was consistent with TcpA, which is the major subunit of the pilus. Thus, we confirmed the expression of TCP under AKI and verified the association of the pilus with the OMVs. These TCP-decorated OMVs were used for an immunization study as described above. Again, LPS quantification using a Purpald assay revealed amounts of LPS in ΔwaaL ΔmsbB OMVs derived from an AKI culture that were similar to those of OMVs isolated from LB grown cultures (see Table S2 in the supplemental material). In general, characterization of the qualitative and quantitative humoral immune response directed against proteins or LPS revealed no differences between the mice immunized with ΔwaaL ΔmsbB OMVs derived from an LB culture or the AKI culture, respectively (data not shown). Additionally, we determined the immune response against TcpA in sera of mice immunized with both versions of the ΔwaaL ΔmsbB OMVs by ELISA (Fig. 9A). The mice immunized with AKI-derived ΔwaaL ΔmsbB OMVs exhibited a small but significant 3-fold increase of antibodies against TcpA compared to the group immunized with the LB-derived OMVs. However, in comparison to the pronounced immune response against other proteins or LPS, the titers against TcpA are quite low. Thus, either the amount of TcpA associated with the OMVs was too low or TcpA is not highly immunogenic in the context of V. cholerae OMVs. Neonatal mice born to dams immunized with AKI-derived ΔwaaL ΔmsbB OMVs were split into two groups and challenged with V. cholerae serogroup O1 or serogroup O139. The O1 challenge revealed a stable colonization of around 10^5 to 10^6 CFU/small intestine and consequently no protection (Fig. 9B). In the case of the O139 challenge, the median colonization rate was 5 × 10^4 CFU/small intestine and therefore slightly reduced compared to nonvaccinated control mice or mice immunized with LB-derived OMVs (Fig. 8B and 9C). Furthermore, one neonatal mouse had no recoverable CFU and two neonatal mice exhibited a very low colonization (Fig. 9C). Nevertheless, a significant reduction of the colonization level, with the majority of mice not colonized, could not be observed. Thus, isolation of OMVs derived from AKI cultures results in the presence of TcpA, but this surface antigen is insufficient to induce a protective immune response and therefore cannot compensate for the lack of the O antigen.

**O antigen antibodies are highly effective in inhibition of motility in vitro and essential for protection in vivo.** Previous results suggested that protection of neonatal mice from V. cholerae infection occurs through the inhibition of bacterial motility by antibodies from OMV-immunized dams (31). We hypothesized that the blockage occurs via antibodies directed against the O antigen, which might bind to the LPS present in the outer membrane sheath that covers the single polar flagellum of V. cholerae. We performed an established in vitro motility assay in which pooled sera of OMV-immunized or nonvaccinated mice as well as specific antibodies were mixed 1:2 with a bacterial suspension of a V. cholerae strain serogroup O1 and examined by dark-field microscopy using a long exposure (Fig. 10A) (31). Motile bacteria appear as swirls or lines, whereas nonmotile bacteria appear as bright dots. Furthermore, we quantified the number of motile bacteria per field in each image (Fig. 10B). Sera from nonvaccinated control mice were used as a control and did not result in any inhibition of motility. Only the use of sera from WT (O1) OMV-immunized mice, which contain O antigen antibodies, as well as the use of commercially available antisera directed against the O1 antigen, results in complete blockage of motility. Neither serum from ΔwaaL ΔmsbB OMV-immunized mice nor FlaA antiserum, targeting the major flagellin subunit of the flagella, nor OmpU antiserum, targeting the most abundant outer membrane porin of V. cholerae, caused a reduction of the motility. For serum blocking motility, viability of V. cholerae was determined by plating for CFU counts after 30 min of incubation. Sera from WT (O1) OMV-immunized mice and commercially available O1 antigen antisera showed no reduction in CFU compared to the PBS control (see Fig. S5 in the supplemental material). Thus, the observed effects cannot be explained by reduced viability upon contact with these sera.
To prove that antibodies directed against the O antigen are sufficient for protection against *V. cholerae* infection, we performed a passive immunization study (Fig. 10C). Naive infant mice were subdivided into five groups and challenged with a defined infection dose of *V. cholerae* serogroup O1 mixed with one of the five antisera also used in the motility assay, separately. The level of protection was measured by the degree of colonization in the small intestine after 24 h. Sera from WT (O1) OMV- or ΔwaaL ΔmsbB OMV-immunized mice served as internal controls for the passive immunization assay, since the respective immunized mice showed either a high or no protective immune response against challenge with *V. cholerae* O1 (Fig. 8A). As expected, mice passively immunized with sera from ΔwaaL ΔmsbB OMV-immunized mice exhibited a high colonization of 10^7 CFU/small intestine, while mice passively immunized with sera from WT (O1) OMV-immunized mice showed only a median colonization of 10^5 CFU. The groups that received anti-O1 antigen antibodies showed a significant 100-fold reduction in their colonization level, whereas the other groups receiving either anti-FlaA or anti-OmpU antibodies were stably colonized, with a median colonization level of around 10^7 CFU/small intestine. Thus, the observed colonization rates in the passive immunization assay reflect the results obtained from the *in vitro* motility assay.

**DISCUSSION**

In previous studies, we introduced OMVs of *V. cholerae* as an alternative vaccine candidate against cholera infections and demonstrated the induction of a robust protective immune response upon immunization with OMVs using the mouse model. So far, we primarily used unmodified *V. cholerae* OMVs with substantial amounts of lipid A as part of the LPS. Such a hexa-acylated lipid A moiety is a very potent activator of TLR-4, which could result in adverse vaccine reactogenicity and safety limitations for human applications. The LPS content can be reduced by detergent extraction, which is applied for production of classical *N. meningitidis* OMV vaccines used to control epidemics of serogroup B disease in Norway, Cuba, Chile, Brazil, and New Zealand. As demonstrated in this study, the O antigen is the dominant protective antigen of the *V. cholerae* OMV vaccine. Thus, we focused on a different approach to minimize the potential toxicity based on the use of *V. cholerae* strains with genetically detoxified LPS.

An important step toward this goal was the recent characterization of a secondary acyltransferase, MsbB, of *V. cholerae* (70, 71). Based on these results, we analyzed OMVs derived from an msbB deletion mutant as a detoxified vaccine candidate. OMVs derived from a ΔmsbB strain demonstrated a significantly lower induction of inflammatory markers compared to WT (O1) OMVs in macrophages, which is consistent with the published literature on underacylated LPS (72, 82, 83). The beneficial effects of mutations resulting in OMV donor strains with underacylated LPS are under investigation for a second generation of OMV-based *N. meningitidis* vaccines (54, 84, 85). The remaining induction of an inflammatory response of detoxified ΔmsbB OMVs might be caused by the residual activity of the underacylated LPS as well as additional components, i.e., lipoproteins, which are activators of the TLR-2 cascade (86). It is noteworthy that the biggest reduction in response to detoxified ΔmsbB OMVs was seen for the pyrogenic cytokine IL-6, which is one of the most important markers for determination of clinical toxicity used by the pharmaceutical industry and national control authorities (87).

Throughout the study, we could not detect any differences in the specificity of the humoral immune response on the protein or on the LPS level between WT (O1) OMV- and ΔmsbB OMV-immunized mice. Naturally, the OMVs with underacylated LPS could have lost some adjuvant activity compared to the WT (O1) OMVs. Indeed, we observed a slight tendency toward a lower im-

---

**FIG 10** Protective immune response correlates with the presence of O antigen antibodies, which inhibit the motility of *V. cholerae*. (A) Shown are representative images using *V. cholerae* serogroup O1 (WT) (OD<sub>600</sub> = 0.16) mixed with nonvaccinated control sera (a), sera of WT (O1) OMV-immunized mice (b), sera of ΔwaaL ΔmsbB OMV-immunized mice (c), anti-O1 antigen antibodies (d), anti-FlaA antibodies (e), and anti-OmpU antibodies (f). After 10 min of incubation, the bacterial motility was visualized by dark-field microscopy using a 456-ms exposure. Motile bacteria appear as lines or swirls and nonmotile bacteria as dots. Bars, 50 μm. (B) Quantification of motility in the presence of nonvaccinated control sera, sera of WT (O1) OMV-immunized mice, sera of ΔwaaL ΔmsbB OMV-immunized mice, anti-O1 antigen antibodies, anti-FlaA antibodies, or anti-OmpU antibodies. Each symbol represents an independent experiment, and the horizontal bar indicates the median of each data set. When no motile bacteria were visible, the number was set to the limit of detection of 1 bacterium/field (dotted line). Significant differences between the data sets are indicated by asterisks (*P* < 0.05; Kruskal-Wallis test and *post hoc* Dunn’s multiple comparisons). (C) Passive immunization of neonates born to naive dams using *V. cholerae* serogroup O1 (WT) mixed with sera of WT (O1) OMV-immunized mice, sera of ΔwaaL ΔmsbB OMV-immunized mice, anti-O1 antigen antibodies, anti-FlaA antibodies, or anti-OmpU antibodies. Significant differences between the data sets are indicated by asterisks (*P* < 0.05; Kruskal-Wallis test and *post hoc* Dunn’s multiple comparisons).
mune response in the mice immunized with ΔmsbB OMVs than in those immunized with WT (O1) OMVs. One could speculate that this might have a negative impact on the efficacy of the OMV vaccine candidate. However, this difference did not affect the induction of a protective immune response in ΔmsbB OMV-immunized mice. Thus, ΔmsbB OMVs still induce a robust immune response, and other components in the OMVs might compensate for the loss of the hexa-acylated lipid A as an internal adjuvant. Based on these results, a complex formulation with accessory buffer solutions and additional adjuvants is unlikely to be required for the ΔmsbB OMVs, which minimizes the production costs of an OMV-based cholera vaccine. Hence, the detoxified OMVs derived from a ΔmsbB strain with attenuated LPS improve the safety of the vaccine candidate and open up the possibility toward a parenteral administration of the vaccine.

An ideal cholera vaccine should protect against both clinically relevant serogroups O1 and O139. We previously reported that immunization with O1 OMVs could not protect against challenge with O139 and vice versa. However, a mixture of O1 OMVs and O139 OMVs provided protection from colonization upon challenge with both serogroups (31). The same report demonstrated that most of the immune response is directed against LPS, indicating that LPS is the most immunogenic antigen in the OMVs (31). In order to avoid the use of an OMV mixture derived from different donors, we wanted to create a single donor strain for the cholera OMV vaccine production. We hypothesized that elimination of the O antigen as the discrimination marker between the serogroups O1 and O139 might result in a serogroup-independent OMV vaccine candidate. Ideally, the lack of the O antigen should redirect the immune response to alternative OMV antigens present in both serogroups.

To analyze such a potential serogroup-independent vaccine candidate, we used OMVs derived from a ΔawaL ΔmsbB strain providing an underacylated LPS without O antigen. In general, the ELISA studies indicate that ΔawaL ΔmsbB OMV-immunized mice induced a humoral immune response at levels comparable to those of WT (O1) OMV-immunized mice. Thus, ΔawaL ΔmsbB OMVs seem to be as immunogenic as WT (O1) OMVs under the tested conditions. However, some distinct differences in the specificity have been observed. Intriguingly, the highest IgG titers in sera of ΔawaL ΔmsbB OMV-immunized mice were revealed only if ΔawaL ΔmsbB OMVs were used as coating material, while a lower immune response was detected if WT (O1) OMVs were used as coating antigen. In contrast, WT (O1) OMV-immunized mice showed comparable high titers independent of the OMV origin. This might indicate that immunization with ΔawaL ΔmsbB OMVs induces a specific subset of antibodies directed against structures that are either not present or are masked in WT (O1) OMVs. Further analysis of the antibody specificity revealed that all three immunization groups exhibited similar protein-directed immune responses, whereas the ΔawaL ΔmsbB OMV-immunized mice differ in their LPS-directed immune response compared to WT (O1) OMV-immunized mice. Naturally, the full-length LPS with substituted O antigen was present only in WT (O1) and ΔmsbB OMVs. Thus, only mice receiving these OMVs produced a substantial amount of anti-O antigen antibodies, whereas such antibodies are absent in mice immunized with ΔawaL ΔmsbB OMVs. Nevertheless, all three immunization groups produced a similar response against the lipid A-core OS.

Immunization with ΔawaL ΔmsbB OMVs failed to induce a protective immune response against both V. cholerae serogroups O1 and O139. Thus, we did not generate a serogroup-independent vaccine candidate but indirectly revealed that antibodies directed against the O antigen are crucial for the protection from colonization upon challenge with V. cholerae. We tested whether the presence of TcpA as an alternative surface antigen might compensate for the lack of the O antigen. TcpA is the major subunit of the main colonization factor TCP and has been suggested as a good target for recombinant subunit vaccines (88–90). Fortunately, expression of TCP can be simply achieved by growing the bacteria in AKI broth (38). Indeed, we found TcpA to be present in the isolated OMVs derived from an AKI culture. However, mice immunized with these OMVs induced only a low immune response against TcpA, and no protection against a challenge using V. cholerae O1 or O139 was observed. Thus, the presence of TcpA, expressed from its natural promoter, in OMVs is not sufficient to compensate for the lack of the O antigen. In order to keep the production costs for an OMV-based cholera vaccine low, we favored a relatively simple isolation protocol based on TCP-inducing culture conditions rather than an expression of TcpA using inducible promoter systems. Hence, we cannot exclude that a larger amount of TcpA in the OMVs would have resulted in higher antibody titers against TcpA and might have induced a protective immune response. If necessary, an alternative approach resulting in high TcpA expression can be revisited, but it does not seem to be an essential requirement for an OMV-based vaccine to include TcpA as an antigen.

Recently, we revealed a correlation between the in vivo protection upon immunization with OMVs and an inhibition of motility of V. cholerae by sera of OMV-immunized mice (31). It was speculated that the anti-LPS antibodies present in the breast milk of the immunized dams block motility of V. cholerae in the neonates and thereby prevent a successful colonization. In concordance with this hypothesis, the sera from WT (O1) OMV-immunized mice blocked motility, while sera from ΔawaL ΔmsbB OMV-immunized mice did not. As demonstrated in this study, ΔawaL ΔmsbB OMV-immunized mice induced a similar immune response against the lipid A-core OS, but not against the O antigen. Thus, we hypothesized that anti-O antigen antibodies are crucial for the inhibition of motility. Using defined antisera, we were able to confirm this hypothesis, as only the antisera directed against the O antigen could block motility. Furthermore, a passive immunization experiment using these antisera revealed that only the anti-O antigen antibodies are capable of reducing the colonization at levels comparable to those of sera from WT (O1) OMV-immunized mice. Thus, we can refine our hypothesis and state that anti-O antigen antibodies are essential to block motility by binding to the sheathed flagellum. Interestingly, neither antisera against the major flagellin, FlaA, nor antisera against the most abundant outer membrane protein, OmpU, could block motility. Thus, these antibodies are either masked by the sheath or not highly abundant in the sheath of the flagellum. Consequently, the O antigen is the dominant protective antigen of the OMV-based cholera vaccine candidate.

Interestingly, the importance of anti-LPS antibodies has been also suggested for other cholera vaccine candidates, including whole-cell killed vaccines, live attenuated vaccines, and subunit vaccines (81, 91–95). It has been speculated that the protective efficacy of anti-LPS antibodies is mediated through either vibriocidal activity or inhibition of adhesion to the epithelial surface (25,
We herein present an alternative mechanism by which anti-O antigen antibodies effectively block motility and thereby prevent effective colonization. Recent epidemiological data revealed a correlation between the presence of LPS-specific IgG memory B cells and protection against infection with *V. cholerae* O1 (99). Furthermore, a recent analysis of the immune response in cholera patients indicates that antibodies predominantly targeting the O antigen of *V. cholerae* correlate with protection against cholera (98). Thus, the induction of an anti-O antigen response seems also to be associated with protection against cholera in humans. These epidemiological correlations and the findings from our immunization study using the mouse model strengthen the idea that the O antigen might be the dominant protective antigen against cholera infections. Hence, a future direction in cholera vaccine design might be to focus on the development of a vaccine specifically inducing long-lasting, high-titer immune responses against the clinically relevant *V. cholerae* O antigens.

Future comparative studies have to prove whether the OMV vaccine candidate is the best delivery vehicle for LPS. Mucosal immunization with purified LPS does not induce a strong antibody response, probably since LPS is a well-established T-cell-independent antigen (100,101). Thus, a simple vaccine based on purified LPS is not applicable. Obviously, OMVs provide a balanced blend of LPS, lipids, and proteins to overcome mucosal tolerance and allow the induction of a robust LPS-directed immune response upon mucosal immunization. Such beneficial properties of OMVs, bacterial ghosts, or artificially engineered liposomes, are currently being addressed by a number of research groups (102). Ongoing studies are focused on comparing the effectiveness of the OMV-based vaccine candidate with that of the whole-cell killed vaccine. So far, we can summarize that the OMV vaccine candidate is temperature stable and can be easily administered (probably without trained health care staff), a mixture of OMVs derived from O1 and O139 induces a protective immune response against both clinically relevant serogroups, detoxification of the OMVs by LPS modifications is possible, and OMVs provide most likely a higher concentration of the relevant O antigen than does the whole-cell killed vaccine (31–33). We can only speculate on the production costs, but feasible large-scale production is demonstrated by the *N. meningitidis* OMV vaccine, and isolation of the OMVs should be cheaper than the production of conjugate subunit vaccines. Immunization with OMVs induces an immune response against a variety of surface structures, although probably only the population of anti-O antigen antibodies is responsible for a protective immune response. However, one cannot exclude that presence of antibodies directed against other surface components than LPS might have additive effects on the protective efficacy.

**ACKNOWLEDGMENTS**

This work was supported by the Austrian FWF grants P25691 to S.S. and W901-B12 (DK Molecular Enzymology) to D. R. L., S. F., J. R., and S. S. We are grateful to Chamal Khoury for critically reading the manuscript and to Thierry Claudel for assistance with the design of the oligonucleotides used for qRT-PCR as well as to J. Kaper and R. Taylor for kindly providing the plasmids pSSH2188 and pET15b-cI-TcpA, respectively.

**REFERENCES**

LPS Modifications of an OMV Vaccine Candidate


